1-3 of 3
Matthew I. Quesenberry, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BrUOG 345: Fractionated Gemtuzumab Ozogamicin Followed By Non-Engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Adam Zayac, MD, Pamela C Egan, MD, Thomas A Ollila, MD, Adam J Olszewski, MD, Peter Barth, MD, Matthew I. Quesenberry, MD, James Butera, MD, Loren D. Fast, PhD, Rabin Niroula, MBBS, Peter J. Quesenberry, MD, John L Reagan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4460.
https://doi.org/10.1182/blood-2019-123789
Published: 2019
Journal Articles

Caplacizumab As Step-up Therapy in Refractory TTP Utilizing Adamts-13 Activity and Evidence of End-Organ Damage

Neel Belani, MD, Adriel Barrios-Anderson, Sc.B, A.B., William Rafelson, MDMBA, Matthew I. Quesenberry, MD, Rabin Niroula, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4909.
https://doi.org/10.1182/blood-2019-123206
Published: 2019
Journal Articles

Marrow Hypocellularity, but Not Residual Blast Count, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia

Thomas Ollila, MD, Adam J Olszewski, MD, Peter J. Quesenberry, MD, Matthew I. Quesenberry, MD, James Butera, MD, John L. Reagan, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1428.
https://doi.org/10.1182/blood.V130.Suppl_1.1428.1428
Published: 2017